Advice
Following an abbreviated submission
latanoprost, timolol (Xalacom®) is accepted for use within NHS Scotland for reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
This abbreviated submission relates to a licence extension to cover use of this medicine in patients insufficiently responsive to a prostaglandin analogue used alone. Xalacom® is suitable for patients in whom timolol and latanoprost are appropriate choices of beta-blocker and prostaglandin analogue respectively. It costs less than the individual preparations.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- latanoprost timolol maleate (Xalacom)
- SMC ID:
- 432/07
- Indication:
- Raised intraocular pressure in patients with open angle glaucoma and ocular hypertension.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 14 January 2008